---
schema_version: "secwatch.filing_event.v1"
accession: "0001323885-22-000097"
form_type: "8-K"
ticker: "ATRC"
cik: "0001323885"
company_name: "AtriCure, Inc."
filed_at: "2022-08-02T23:59:59+00:00"
generated_at: "2026-06-24T05:45:50.989774+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AtriCure Q2 2022 revenue $84.5M (+18.4%); net loss $0.32/share; FY guidance unchanged

## Summary
- Revenue $84.5M (+18.4% YoY; +19.8% constant currency); U.S. $71.3M (+18.6%), international $13.3M (+17.3%).
- Gross margin 75.1% vs 75.8% prior; operating loss $13.7M vs $15.1M prior.
- Net loss per share $0.32 (adjusted $0.32) vs $0.36 GAAP and $0.30 adjusted prior year.
- Adjusted EBITDA loss $3.2M vs $2.7M prior; FY 2022 revenue guide $323M-$333M (18-21% growth).
- Growth driven by cryoSPHERE, AtriClip, ENCOMPASS, and EPi-Sense products.

## SEC filing metadata
- accession: 0001323885-22-000097
- form_type: 8-K
- ticker: ATRC
- cik: 0001323885
- company_name: AtriCure, Inc.
- filed_at: 2022-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1323885/000132388522000097/0001323885-22-000097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1323885/000132388522000097/atrc-20220802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001323885-22-000097
- JSON: https://secwatch.observer/filing/0001323885-22-000097.json
- Plain text: https://secwatch.observer/filing/0001323885-22-000097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.